Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
30.15
+0.07 (0.23%)
At close: Feb 18, 2026, 4:00 PM EST
29.57
-0.58 (-1.92%)
After-hours: Feb 18, 2026, 4:29 PM EST

Edgewise Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-157.24-133.81-100.16-67.64-42.81-17.12
Depreciation & Amortization
2.322.291.730.540.270.19
Loss (Gain) From Sale of Investments
-8.78-12.55-9.52-0.54--
Stock-Based Compensation
32.6124.7117.5610.924.40.35
Change in Accounts Payable
0.671.74-0.090.052.650.52
Change in Other Net Operating Assets
-1.768.59-1.474.041.981.43
Operating Cash Flow
-132.18-109.03-91.95-52.64-33.51-14.63
Capital Expenditures
-0.46-1.31-5.75-5.55-0.67-0.2
Investment in Securities
-61.17-183.34108.63-65.03-241.56-24.18
Investing Cash Flow
-61.63-184.66102.89-70.58-242.23-24.38
Issuance of Common Stock
195.01249.5253.33129.89186.510.2
Other Financing Activities
--0.26-0.17-0.25-0.12-
Financing Cash Flow
195.01249.2553.17129.64186.38120.28
Net Cash Flow
1.2-44.4364.16.43-89.3581.26
Free Cash Flow
-132.64-110.34-97.69-58.18-34.18-14.84
Free Cash Flow Per Share
-1.32-1.19-1.53-1.09-0.91-20.08
Levered Free Cash Flow
-79.61-63.22-61.66-35.48-19.26-7.36
Unlevered Free Cash Flow
-79.61-63.22-61.66-35.48-19.26-7.36
Change in Working Capital
-1.0910.33-1.564.094.631.95
Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q